Fundraising Fox

CHASE Pharmaceuticals

Washington, US · 2 known investors

Founders & leadership

TN
Thomas N. ChaseFounder
DI
Douglas IngramExecutive
KC
Kathleen Clarence-SmithNamed on SEC filing
GN
Greg N. ParekhNamed on SEC filing
JM
John M. SiebertNamed on SEC filing

Board

NG
Nayan Greg ParekhBoard director
JM
John M. ReherBoard directorManaging Director at Brain Trust Accelerator Fund
RW
Raphael WisniewskiBoard director
SC
Stephen CunninghamBoard director
VS
Vikram SudarsanBoard director
KN
Karoly NikolichBoard director

Investors · 2

Reported raises · per SEC filings

Form D private placements

$21.6M disclosed across 3 of 5 rounds · 2014–2016

$12MraisedMar 2016 · 14 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Kathleen Clarence-SmithExecutive Officer
  • Vikram SudarsanDirector
  • Raphael WisniewskiDirector
  • Stephen CunninghamDirector
  • Nayan Greg ParekhDirector
  • Karoly NikolichDirector
  • John M. ReherDirector
  • Thomas N. ChaseExecutive Officer, Director
Offering amount
$12M
Amount sold
$12M
First sale
Mar 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$106.7KofferedFeb 2016 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen CunninghamDirector
  • Raphael WisniewskiDirector
  • Vikram SudarsanDirector
  • Nayan Greg ParekhDirector
  • John M. ReherDirector
  • Thomas N. ChaseExecutive Officer, Director
  • Karoly NikolichDirector
  • Kathleen Clarence-SmithExecutive Officer
  • Douglas IngramExecutive Officer, Director
Offering amount
$106.7K
First sale
Dec 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$3.5MraisedFeb 2016 · 13 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Raphael WisniewskiDirector
  • Vikram SudarsanDirector
  • Stephen CunninghamDirector
  • Nayan Greg ParekhDirector
  • John M. ReherDirector, Executive Officer
  • Thomas N. ChaseExecutive Officer, Director
  • Karoly NikolichDirector
  • Douglas IngramDirector
  • Kathleen Clarence-SmithExecutive Officer
Offering amount
$3.5M
Amount sold
$3.5M
First sale
Aug 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$612.5KofferedFeb 2016 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Nayan Greg ParekhDirector
  • Karoly NikolichDirector
  • Kathleen Clarence-SmithExecutive Officer
  • John M. ReherDirector
  • Raphael WisniewskiDirector
  • Douglas IngramExecutive Officer, Director
  • Thomas N. ChaseExecutive Officer, Director
  • Stephen CunninghamDirector
  • Vikram SudarsanDirector
Offering amount
$612.5K
First sale
Jan 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$6.1MraisedMay 2014 · 6 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Raphael WisniewskiDirector
  • Greg N. ParekhDirector
  • Vikram SudarsanDirector
  • Thomas N. ChaseDirector
  • John M. ReherDirector
  • John M. SiebertExecutive Officer, Director
  • Karoly NikolichDirector
Offering amount
$8.6M
Amount sold
$6.1M
Minimum investment
$1
First sale
May 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

Who founded CHASE Pharmaceuticals?
CHASE Pharmaceuticals was founded by Thomas N. Chase.
Who are CHASE Pharmaceuticals's investors?
CHASE Pharmaceuticals's investors include Andera Partners, Brain Trust Accelerator Fund.
How much funding has CHASE Pharmaceuticals raised?
CHASE Pharmaceuticals has disclosed $21.6M raised across 3 of its 5 known rounds.
Where is CHASE Pharmaceuticals headquartered?
CHASE Pharmaceuticals is headquartered in Washington, US.